Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children

Journal of Pediatrics

Volumn 145, Issue 3, 2004, Pages 403-405

  Burger, David M ^a,b   Bergshoeff, Alina S ^a   De Groot, Ronald ^a   Gibb, Diana ^a   Walker, Sarah ^a   Tréluyer, Jean Marc ^a   Hoetelmans, Richard M W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Clinical Pharmacy   (Netherlands)

Author keywords

Pediatric European Network for Treatment of AIDS; PENTA

Indexed keywords

NELFINAVIR; PROTEINASE INHIBITOR;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; VIRUS LOAD;

CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; NELFINAVIR;

EID: 4444299669     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2004.04.048     Document Type: Article

References (11)

1. Pellegrin I., Breilh D., Montestruc F., Caumont A., Garrigue I., Morlat P., et al. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS. 16:2002;1331-1340
2. Hoetelmans R.M.W., Reijers M.H.E., Weverling G.J., Kate tR.W., Wit F.W.N.M., Mulder J.W., et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS. 12:1998;F111-F115
3. Powderly W.G., Saag M.S., Chapman S., Yu G., Quart B., Clendeninn N.J. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 13:1999;1873-1880
4. Burger D.M., Hugen P.W., Aarnoutse R.E., Hoetelmans R.M., Jambroes M., Nieuwkerk P.T., et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit. 25:2003;73-80
5. Burger D., Hugen P., Reiss P., Gyssens I., Schneider M., Kroon F., et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 17:2003;1157-1165
6. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet. 359:2002;733-740
7. Anonymous. Optimising TDM in HIV clinical care: a practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents. Available: http://www.HIVpharmacology.com Last visited at September 12, 2003.
8. Hsyu PH, Capparelli EV, Amantea M, Petersen A, Kerr BM. Population Pharmacokinetics (PK) of TID Nelfinavir (NFV) and Correlation to Efficacy in Pediatric Patients. 1st IAS Conference on HIV Pathogenesis and Treatment, 2001, abstract 348. 2002.
9. Ref Type: Abstract.
10. Gatti G., Castelli-Gattinara G., Cruciani M., Bernardi S., de Pascalis C.R., Pontali E., et al. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Clin Infect Dis. 36:2003;1476-1482
11. Bergshoeff A.S., Fraaij P.L., van Rossum A.M., Wolfs T.F., Geelen S.P., de Groot R., et al. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir Ther. 8:2003;215-222